Literature DB >> 21063850

The role of high-sensitivity C-reactive protein, interleukin-6 and cystatin C in ischemic stroke complicating atrial fibrillation.

Ling You1, Peihua Wang, Jiagao Lv, Katherine Cianflone, Daowen Wang, Chunxia Zhao.   

Abstract

This study examined the role of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and cystatin C in ischemic stroke complicating atrial fibrillation (AF) and the relationship of systemic inflammation with this disease in order to identify AF patients who are at high risk of stroke and need optimal anticoagulant therapy. A total of 103 AF patients, simple (n=75) or complicated by ischemic stroke (n=28), and 112 control subjects were recruited. IL-6 level was detected by using enzyme linked immunosorbent assay. Cystatin C and hsCRP levels were measured by means of a particle-enhanced immunonephelometric assay. The results showed that the AF patients had higher levels of hsCRP (P=0.004), IL-6 (P=0.000), and cystatin C (P=0.000) than control subjects. Plasma hsCRP level was increased in the AF patients with ischemic stroke as compared to the patients with simple AF (P=0.036). The AF patients who had the level of hsCRP exceeding 3.83 mg/L were at a higher risk than those with hsCRP level lower than 3.83 mg/L (P=0.030). After adjusting for other factors, cystatin C remained positively associated with IL-6 (r=0.613) and hsCRP (r=0.488). It was concluded that hsCRP is positively correlated with ischemic stroke complicating AF and may be a risk factor independent of other risk factors for AF. Elevated cystatin C level is also indicative of the increased risk of AF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063850     DOI: 10.1007/s11596-010-0558-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  24 in total

1.  Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.

Authors: 
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

2.  Cystatin C and contrast-induced acute kidney injury.

Authors:  Carlo Briguori; Gabriella Visconti; Natalia V Rivera; Amelia Focaccio; Bruno Golia; Rosalia Giannone; Diletta Castaldo; Francesca De Micco; Bruno Ricciardelli; Antonio Colombo
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

Review 3.  Is atrial fibrillation an inflammatory disorder?

Authors:  Christopher J Boos; Richard A Anderson; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2005-11-08       Impact factor: 29.983

4.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).

Authors:  C D Furberg; B M Psaty; T A Manolio; J M Gardin; V E Smith; P M Rautaharju
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

5.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation.

Authors:  Stavroula N Psychari; Thomas S Apostolou; Loukas Sinos; Eftihia Hamodraka; George Liakos; Dimitrios Th Kremastinos
Journal:  Am J Cardiol       Date:  2005-03-15       Impact factor: 2.778

6.  Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques.

Authors:  Hiroshi Yamagami; Kazuo Kitagawa; Yoji Nagai; Hidetaka Hougaku; Manabu Sakaguchi; Keisuke Kuwabara; Kimito Kondo; Tohru Masuyama; Masayasu Matsumoto; Masatsugu Hori
Journal:  Stroke       Date:  2004-01-29       Impact factor: 7.914

7.  Thromboembolism in patients with atrial fibrillation.

Authors:  D G Sherman; L Goldman; R B Whiting; K Jurgensen; M Kaste; J D Easton
Journal:  Arch Neurol       Date:  1984-07

8.  Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese.

Authors:  Li Ni; Jiagao Lü; Ling Bo Hou; Jiang Tao Yan; Qiao Fan; Rutai Hui; Katherine Cianflone; Wei Wang; Dao Wen Wang
Journal:  Stroke       Date:  2007-10-18       Impact factor: 7.914

9.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

10.  Inflammation as a risk factor for atrial fibrillation.

Authors:  Ronnier J Aviles; David O Martin; Carolyn Apperson-Hansen; Penny L Houghtaling; Pentti Rautaharju; Richard A Kronmal; Russell P Tracy; David R Van Wagoner; Bruce M Psaty; Michael S Lauer; Mina K Chung
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

View more
  5 in total

1.  Cardiac Immunology: A New Era for Immune Cells in the Heart.

Authors:  Arzuhan Koc; Esra Cagavi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Elevated Serum Beta-Trace Protein Levels are Associated With the Presence of Atrial Fibrillation in Hypertension Patients.

Authors:  Muhammed U Yalcin; Kadri M Gurses; Duygu Kocyigit; Sacit A Kesikli; Lale Tokgozoglu; Dicle Guc; Kudret Aytemir; Necla Ozer
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-05       Impact factor: 3.738

3.  TLR2 was overexpressed independent of IL-6 in patients with valvular atrial fibrillation.

Authors:  Jian Wang; Lei Xue; Hailong Cao; Fei Cui; Ting Dai; Yijiang Chen
Journal:  J Biomed Res       Date:  2011-05

Review 4.  The Predictive Role of Inflammatory Biomarkers in Atrial Fibrillation as Seen through Neutrophil-Lymphocyte Ratio Mirror.

Authors:  Feliciano Chanana Paquissi
Journal:  J Biomark       Date:  2016-07-03

5.  Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.

Authors:  Piotr Kusak; Danuta Czarnecka; Matthew Gissel; Krzysztof Plens; Saulius Butenas; Anetta Undas
Journal:  Arch Med Sci       Date:  2015-11-17       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.